

Cover Story
Guest Editorial
By John H. Stewart and Robert A. Winn
Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.
By Claire Dietz and Matthew Bin Han Ong
In Brief
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality - Kay “Taddy” Dickersin, NBCC co-founder, dies at 74















